ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
IL-3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Microglia play a crucial role in the progression of neuroinflammation following traumatic brain injury (TBI). Interleukin-3 (IL-3), a significant regulatory factor, has been involved in the pathogenesis of various diseases, yet its effects on neuroinflammation post-TBI through microglia remain unclear. Here, we evaluate the potential of IL-3 to alleviate neuroinflammation in microglia following TBI. Using the ABplex Multi-Metric Streaming Joint Analysis to detect inflammatory factors, we observed significantly elevated levels of IL-3 in cerebrospinal fluid, but not in blood samples, of patients with headaches and TBI. In addition, we found that administration of exogenous IL-3 within the brain reduced neuroinflammation and promoted functional recovery in rat TBI models. Mechanistically, we identified Peroxiredoxin-1 (PRDX1) as the target of IL-3 in microglia. Notably, the protective effects of IL-3 in TBI rats were abolished when PRDX1 was specifically knocked down in microglia. In conclusion, our experimental research demonstrates that IL-3 acts as a key modulator via regulating microglia polarization to inhibit neuroinflammation. IL-3 improves neurological function and prognosis in TBI rats by recruiting PRDX1 through IL-3R to modulate microglia polarization. Therefore, IL-3 may represent a novel therapeutic strategy for TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.